| Nov 5 |
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
|
| Nov 5 |
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings
|
| Nov 5 |
Hims & Hers to launch a generic for Novo’s older GLP-1
|
| Nov 5 |
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
|
| Nov 5 |
Allurion boasts over 17% weight loss with swallowable balloon device
|
| Nov 5 |
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
|
| Nov 5 |
Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.
|
| Nov 4 |
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
|
| Nov 4 |
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
|
| Nov 4 |
Viking Therapeutics stock falling amid results for new GLP-1 pill
|
